Spravato cost guide

Spravato Cost Without Insurance in New York

Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant.

Start your Spravato evaluation Call (917) 985-9186

Out-of-pocket cost depends on diagnosis, plan design, and prior authorization

Medicaid, Medicare, Medicare Advantage, and commercial coverage may reduce patient responsibility

Benefits are reviewed before treatment starts

Main Spravato team explains next steps before the first monitored session

Accessible Spravato care in New York

SPRAVATO care requires repeated monitored visits. Ask about a convenient clinic, care-manager support and scheduling, and confirm coverage for the clinician and treatment under your exact insurance plan.

Spravato medication and monitoring costs

No. Ask which costs cover the Spravato medicine, supervised administration, monitoring, psychiatric assessment and continuing reviews. Transport can create a separate practical expense. Confirm the benefit route, approved treatment dates, session limits, pharmacy and patient responsibility. Manufacturer assistance has eligibility rules and does not establish the total clinic charge. A payer approving one dose or course does not guarantee a renewal or payment of every claim. Request the proposed costs before the session and clarify changes in coverage, deductibles or authorized frequency.

Spravato (esketamine nasal spray)

Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behaviour; that use requires an oral antidepressant. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behaviour, and it does not replace hospitalization when that is needed.

Eligibility: Spravato (esketamine nasal spray)

Assessment reviews the diagnosis, previous treatments and whether they were taken at an adequate dose and duration. The clinician checks blood pressure, cardiovascular and cerebrovascular history, psychosis, substance-use risks, pregnancy and interacting medicines. Aneurysmal vascular disease, arteriovenous malformation, a history of intracerebral hemorrhage and hypersensitivity are labelled contraindications. Insurer criteria can differ from the clinical label.

What to expect: Spravato (esketamine nasal spray)

Review treatment history and the intended indication

Bring antidepressant names, doses, dates, response, adverse effects and relevant hospital records. Clarify whether the proposed treatment is TRD care or the separate acute suicidal MDD indication. Discuss other suitable treatments and continuing therapy.

Plan a supervised treatment visit

Spravato is administered through its REMS in a certified healthcare setting. Patients self-administer the nasal spray under direct supervision. Blood pressure is checked before dosing, around 40 minutes afterwards and further as needed. Breathing is monitored, including pulse oximetry, for at least two hours. Release occurs only when the clinician finds the patient stable. Some visits take longer.

Review benefit and frequency

TRD treatment is twice weekly for the first four weeks, then weekly in weeks five through eight. From week nine, dosing is weekly or every two weeks according to response. The clinician assesses benefit after the initial four weeks. The acute suicidal MDD regimen is a separate twice-weekly four-week course. Longer use for that indication has not been systematically evaluated.

Preparing for your appointment

Arrange transport home and leave time for the observation period. Do not eat for at least two hours before a dose or drink liquids for at least 30 minutes before it. If using a nasal corticosteroid or decongestant, follow the label’s timing of at least one hour before Spravato. Bring the medicine list and report alcohol, sedatives, opioids or new symptoms. Do not change other medicines without instructions.

Risks and when to seek help

The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours associated with antidepressants in younger people. Do not drive, operate machinery or undertake activities requiring full alertness until the next day after a restful sleep. Arrange a ride home even if you feel ready to drive. Blood-pressure elevation can make a session unsuitable. Spravato may harm the fetus during pregnancy and breastfeeding is not recommended during treatment. Urgent worsening depression or a suicide crisis needs immediate clinical or emergency care rather than waiting for the next session.

Follow-up and treatment review

Track depression symptoms, daily function, adverse effects and missed sessions with the treating team. A late session is not a reason to double a dose. If maintenance sessions are missed and symptoms worsen, the clinician may consider returning to a previous frequency. Continuing care includes psychiatric review and safety planning, not just attendance at nasal-spray visits.

Appointments, costs and coverage

Ask for separate confirmation of medication coverage, administration and monitoring charges, authorization dates and the number of approved visits. A previous approval does not guarantee a new dose, renewal or paid claim. Ask about appeals and documentation if denied. Confirm the selected site’s REMS status, appointment capacity and transport policy directly. Ask whether the medicine is ready and which charges are approved.